New Directions in Research, Care Focus of Les Turner ALS Symposium

Surviving the Threat of a Bomb With a Dose of Aplomb

“All our times have come Here but now they’re gone Seasons don’t fear the reaper Nor do the wind, the sun, or the rain We can be like they are.” I was 18 years old when the band Blue Oyster Cult released the song “(Don’t Fear) The Reaper.” Coinciding…

Former NFL Player Tim Green Won’t Let ALS Define Him

Once a first-round draft pick for the Atlanta Falcons, Tim Green now is battling another opponent — amyotrophic lateral sclerosis (ALS). The disease has left him unable to walk, speak, eat, drink, or breathe on his own, but he hasn’t let it obscure his positive outlook on life. “I…

TQS-168 Found to Reduce Inflammation, Extend Survival in Mice

TQS-168, an investigational therapy being developed by Tranquis Therapeutics, reduced inflammation in mouse and human models of amyotrophic lateral sclerosis (ALS), and prolonged survival in the mice, according to a preclinical study. Based on these findings, Tranquis is moving the therapy into Phase 1 clinical studies. “We believe…

Unexpected Outcomes From Sharing Our Story

“Your YouTube channel must be taking off,” my 15-year-old daughter said. “Your edema video was recommended to me again. I was just scrolling through YouTube, and then I see it, and I’m like, ‘What’s this?’” Sara continued with increasing volume: “Oh, that’s my father’s foot! My father’s foot has…

A Sign of the Times — Could They Be a-Changin’?

“All the Bush League batters Are left to die on the diamond In the stands the home crowd scatters For the turnstiles.” Twice in my post-ALS life, Neil Young’s song “For the Turnstiles” has struck me smack dab in the center of my forehead. As the dust finally settled…

Dosing Begins in Phase 3 PHOENIX Trial of AMX0035

Amylyx Pharmaceuticals‘ global Phase 3 clinical trial investigating AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS) has begun dosing participants. The PHOENIX trial (NCT05021536) is expected to include 600 participants whose symptoms began in the past two years, which is a less-stringent criteria than was required for…